Author

Evan S. Dellon

DUPILUMAB EFFICACY AND SAFETY UP TO 52 WEEKS IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A AND C OF A RANDOMIZED, PLACEBO-CONTROLLED, THREE-PART, PHASE 3 LIBERTY EOE TREET STUDY
DUPILUMAB EFFICACY AND SAFETY UP TO 52 WEEKS IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A AND C OF A RANDOMIZED, PLACEBO-CONTROLLED, THREE-PART, PHASE 3 LIBERTY EOE TREET STUDY

New drugs in EoE
New drugs in EoE

Evan S. Dellon

DIFFERENCES IN TREATMENT PATTERNS AMONG PATIENTS DIAGNOSED WITH EOSINOPHILIC OESOPHAGITIS IN THE UNITED STATES
DIFFERENCES IN TREATMENT PATTERNS AMONG PATIENTS DIAGNOSED WITH EOSINOPHILIC OESOPHAGITIS IN THE UNITED STATES

COMPLIANCE FOR THE PROSE DAILY DIARY: MEASURING COMPLETION RATES OF A NEW INSTRUMENT TO MEASURE DYSPHAGIA EPISODES IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS
COMPLIANCE FOR THE PROSE DAILY DIARY: MEASURING COMPLETION RATES OF A NEW INSTRUMENT TO MEASURE DYSPHAGIA EPISODES IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS

Evan S. Dellon  et al.

DUPILUMAB EFFICACY AND SAFETY UP TO 52 WEEKS IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PARTS B AND C OF THE RANDOMIZED, PLACEBO-CONTROLLED, THREE-PART, PHASE 3 LIBERTY EOE TREET STUDY
DUPILUMAB EFFICACY AND SAFETY UP TO 52 WEEKS IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PARTS B AND C OF THE RANDOMIZED, PLACEBO-CONTROLLED, THREE-PART, PHASE 3 LIBERTY EOE TREET STUDY

Evan S. Dellon  et al.

SAFETY AND EFFICACY OF LONG-TERM TREATMENT WITH LIRENTELIMAB, A MONOCLONAL ANTIBODY AGAINST SIGLEC-8, IN PATIENTS WITH EOSINOPHILIC GASTRITIS/DUODENITIS
SAFETY AND EFFICACY OF LONG-TERM TREATMENT WITH LIRENTELIMAB, A MONOCLONAL ANTIBODY AGAINST SIGLEC-8, IN PATIENTS WITH EOSINOPHILIC GASTRITIS/DUODENITIS

Evan S. Dellon  et al.

DUPILUMAB IMPROVES HISTOLOGICAL AND ENDOSCOPIC FEATURES OF EOSINOPHILIC OESOPHAGITIS IN CHILDREN AGED 1–11 YEARS IN THE PHASE 3 EOE KIDS TRIAL
DUPILUMAB IMPROVES HISTOLOGICAL AND ENDOSCOPIC FEATURES OF EOSINOPHILIC OESOPHAGITIS IN CHILDREN AGED 1–11 YEARS IN THE PHASE 3 EOE KIDS TRIAL

DUPILUMAB EFFICACY AND SAFETY UP TO 52 WEEKS IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A AND C OF A RANDOMIZED, PLACEBO-CONTROLLED, THREE-PART, PHASE 3 LIBERTY EOE TREET STUDY
DUPILUMAB EFFICACY AND SAFETY UP TO 52 WEEKS IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A AND C OF A RANDOMIZED, PLACEBO-CONTROLLED, THREE-PART, PHASE 3 LIBERTY EOE TREET STUDY

Evan S. Dellon  et al.

SAFETY AND EFFICACY OF LONG-TERM TREATMENT WITH LIRENTELIMAB, A MONOCLONAL ANTIBODY AGAINST SIGLEC-8, IN PATIENTS WITH EOSINOPHILIC GASTRITIS/DUODENITIS
SAFETY AND EFFICACY OF LONG-TERM TREATMENT WITH LIRENTELIMAB, A MONOCLONAL ANTIBODY AGAINST SIGLEC-8, IN PATIENTS WITH EOSINOPHILIC GASTRITIS/DUODENITIS

DUPILUMAB IMPROVES HISTOLOGICAL AND ENDOSCOPIC FEATURES OF EOSINOPHILIC OESOPHAGITIS IN CHILDREN AGED 1–11 YEARS IN THE PHASE 3 EOE KIDS TRIAL
DUPILUMAB IMPROVES HISTOLOGICAL AND ENDOSCOPIC FEATURES OF EOSINOPHILIC OESOPHAGITIS IN CHILDREN AGED 1–11 YEARS IN THE PHASE 3 EOE KIDS TRIAL

Evan S. Dellon  et al.

EFFICACY OF DUPILUMAB IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS AND PRIOR USE OR PRIOR INADEQUATE RESPONSE, INTOLERANCE, OR CONTRAINDICATION TO SWALLOWED TOPICAL CORTICOSTEROIDS: RESULTS FROM PART C OF THE LIBERTY EOE TREET STUDY
EFFICACY OF DUPILUMAB IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS AND PRIOR USE OR PRIOR INADEQUATE RESPONSE, INTOLERANCE, OR CONTRAINDICATION TO SWALLOWED TOPICAL CORTICOSTEROIDS: RESULTS FROM PART C OF THE LIBERTY EOE TREET STUDY

Evan S. Dellon  et al.

DUPILUMAB IMPROVES CLINICAL, SYMPTOMATIC, HISTOLOGIC, AND ENDOSCOPIC ASPECTS OF EOE, REGARDLESS OF PRIOR SWALLOWED TOPICAL STEROID USE
DUPILUMAB IMPROVES CLINICAL, SYMPTOMATIC, HISTOLOGIC, AND ENDOSCOPIC ASPECTS OF EOE, REGARDLESS OF PRIOR SWALLOWED TOPICAL STEROID USE

Evan S. Dellon  et al.

IMPACT OF AN ONLINE CONTINUING MEDICAL EDUCATION CURRICULUM ON THE KNOWLEDGE, COMPETENCE, AND CONFIDENCE OF CLINICIANS WHO CARE FOR PATIENTS WITH EOSINOPHILIC OESOPHAGITIS
IMPACT OF AN ONLINE CONTINUING MEDICAL EDUCATION CURRICULUM ON THE KNOWLEDGE, COMPETENCE, AND CONFIDENCE OF CLINICIANS WHO CARE FOR PATIENTS WITH EOSINOPHILIC OESOPHAGITIS

Evan S. Dellon  et al.

DUPILUMAB IN PAEDIATRIC PATIENTS WITH EOSINOPHILIC OESOPHAGITIS – DESIGN OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN CHILDREN AGED 1–11 YEARS, WITH ACTIVE EOSINOPHILIC OESOPHAGITIS
DUPILUMAB IN PAEDIATRIC PATIENTS WITH EOSINOPHILIC OESOPHAGITIS – DESIGN OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN CHILDREN AGED 1–11 YEARS, WITH ACTIVE EOSINOPHILIC OESOPHAGITIS

Evan S. Dellon  et al.

DUPILUMAB IS EFFECTIVE IN TREATING EOE REGARDLESS OF BASELINE WEIGHT OR BMI: POOLED RESULTS FROM PART A AND PART B OF THE LIBERTY EOE TREET STUDY
DUPILUMAB IS EFFECTIVE IN TREATING EOE REGARDLESS OF BASELINE WEIGHT OR BMI: POOLED RESULTS FROM PART A AND PART B OF THE LIBERTY EOE TREET STUDY

Evan S. Dellon  et al.

DYSPHAGIA DAYS AS A CLINICAL MARKER OF EOE TREATMENT RESPONSE
DYSPHAGIA DAYS AS A CLINICAL MARKER OF EOE TREATMENT RESPONSE

Evan S. Dellon  et al.

DIFFERENCES IN TREATMENT PATTERNS AMONG PATIENTS DIAGNOSED WITH EOSINOPHILIC OESOPHAGITIS IN THE UNITED STATES
DIFFERENCES IN TREATMENT PATTERNS AMONG PATIENTS DIAGNOSED WITH EOSINOPHILIC OESOPHAGITIS IN THE UNITED STATES

Evan S. Dellon  et al.

A SURVEY BASED ASSESSMENT OF MANAGEMENT OF ESOPHAGEAL FOOD IMPACTIONS IN THE US AND EUROPE
A SURVEY BASED ASSESSMENT OF MANAGEMENT OF ESOPHAGEAL FOOD IMPACTIONS IN THE US AND EUROPE

Evan S. Dellon  et al.

HIGH DISCOVERY RATE OF EOSINOPHILIC GASTRITIS AND/OR DUODENITIS AMONG PATIENTS WITH CHRONIC FUNCTIONAL GASTROINTESTINAL SYMPTOMS
HIGH DISCOVERY RATE OF EOSINOPHILIC GASTRITIS AND/OR DUODENITIS AMONG PATIENTS WITH CHRONIC FUNCTIONAL GASTROINTESTINAL SYMPTOMS

Evan S. Dellon  et al.

Item 1 - 19 / 19
1